Migragen Acquires Exclusive Patent-License from Yale University

dyonisos · 01-31-2003, 07:02 AM

Migragen Acquires Exclusive Patent-License from Yale University.
Migragen AG announced today that it concluded a licensing agreement with Yale University on a joint patent application on an innovative approach to nerve regeneration. Under this agreement Migragen has acquired the exclusive worldwide rights to use the joint invention for development and commercialization of novel therapeutics. Migragen is an emerging biopharmaceutical company focused in the areas of CNS injury, degenerative CNS diseases and brain tumors.
Migragen and Stephen Strittmatter, M.D. professor and Vincent Coates chair in neurology at Yale School of Medicine have a longstanding research cooperation in the field of nerve regeneration. Dr. Strittmatter, is also a member of the scientific advisory board of Migragen. In January 2002 Migragen obtained its first exclusive license from Yale on its patent on inhibitors of Rho for nerve regeneration. Rho is an enzyme which forms a central regulator in the control of nerve fiber growth and nerve fiber regeneration. Migragen has an inhibitor of Rho under preclinical development for the treatment of spinal cord injury.
The normal development and outgrowth of nerve cells is tightly regulated, also by locally released substances. Upon injury of a mature nerve, such endogenous inhibitory substances are released or locally upregulated at the injury site. Regeneration and outgrowth of the damaged nerve is then inhibited. In the research collaboration between Dr. Strittmatter and Migragen scientists, the receptor for one of these endogenous substances was identified. Compounds which act on this receptor may proof to be useful drugs for therapy of neurodegenerative diseases including traumatic brain injury, stroke and Alzheimer's disease.
(Jan. 2003)

Chris Chappell · 01-31-2003, 12:41 PM

dyonisos, good post. Thank you.

Interesting news. Yale often seems to pop up as a pretty progressive lab, etc. in the world of CNS and SCI.

They may end up being a place for us to review closer as these relationships materialize.

01-31-2003, 07:02 AM	#1
dyonisos Member Join Date: Oct 2002 Location: GERMANY Posts: 54	Migragen Acquires Exclusive Patent-License from Yale University Migragen Acquires Exclusive Patent-License from Yale University. Migragen AG announced today that it concluded a licensing agreement with Yale University on a joint patent application on an innovative approach to nerve regeneration. Under this agreement Migragen has acquired the exclusive worldwide rights to use the joint invention for development and commercialization of novel therapeutics. Migragen is an emerging biopharmaceutical company focused in the areas of CNS injury, degenerative CNS diseases and brain tumors. Migragen and Stephen Strittmatter, M.D. professor and Vincent Coates chair in neurology at Yale School of Medicine have a longstanding research cooperation in the field of nerve regeneration. Dr. Strittmatter, is also a member of the scientific advisory board of Migragen. In January 2002 Migragen obtained its first exclusive license from Yale on its patent on inhibitors of Rho for nerve regeneration. Rho is an enzyme which forms a central regulator in the control of nerve fiber growth and nerve fiber regeneration. Migragen has an inhibitor of Rho under preclinical development for the treatment of spinal cord injury. The normal development and outgrowth of nerve cells is tightly regulated, also by locally released substances. Upon injury of a mature nerve, such endogenous inhibitory substances are released or locally upregulated at the injury site. Regeneration and outgrowth of the damaged nerve is then inhibited. In the research collaboration between Dr. Strittmatter and Migragen scientists, the receptor for one of these endogenous substances was identified. Compounds which act on this receptor may proof to be useful drugs for therapy of neurodegenerative diseases including traumatic brain injury, stroke and Alzheimer's disease. (Jan. 2003)

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

01-31-2003, 12:41 PM	#2
Chris Chappell Senior Member Join Date: Jul 2001 Location: Denver, CO Posts: 7,035	dyonisos, good post. Thank you. Interesting news. Yale often seems to pop up as a pretty progressive lab, etc. in the world of CNS and SCI. They may end up being a place for us to review closer as these relationships materialize.